title: Allergy immunotherapy as an early intervention in patients with child-onset atopic asthma.
abstract: BACKGROUND
  In patients with bronchial asthma an effective treatment is required at early stages of the disease to prevent irreversible structural changes of the airways. The objective of this study was to evaluate the beneficial effects of our routine immunotherapy as an early intervention on FEV1 in patients with child-onset atopic asthma.
  
  
  METHODS
  Beneficial effects of successful immunotherapy on FEV1 were analyzed retrospectively in 43 unselected patients who received our routine standard subcutaneous immunotherapy with periodic FEV1 measurements and became asymptomatic.
  
  
  RESULTS
  Although there was no significant correlation between the duration of asthma symptoms prior to immunotherapy and the changes in FEV1 before and after immunotherapy in 43 unselected patients, there was a significant inverse correlation between these two parameters in 23 patients whose asthma duration was less than 20 years. As the FEV1 increased after immunotherapy in all 14 patients whose asthma duration was less than 5 years, the 43 patients were divided into a group 1 including these 14 patients and a group 2 including 29 patients whose asthma duration was more than 5 years. The FEV1 decreased in 7 of the 29 asymptomatic patients in group 2. There was no difference in the initial FEV1 between the two groups, but the final FEV1 and the mean of the average increase in FEV1 per year by immunotherapy were significantly higher in group 1 than in group 2.
  
  
  CONCLUSIONS
  Immunotherapy should be started as early as possible at the youngest age in order to increase a beneficial effect of successful immunotherapy on FEV1 improvement.
authors.affiliation: Department of Allergy, Kugayama Hospital, Tokyo, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nagaya
authors.forename: Stephen
authors.initials: S
authors.lastname: Maren
authors.forename: Naomi
authors.initials: N
authors.lastname: Nagaya
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000485:Allergens